Created at Source Raw Value Validated value
June 25, 2024, noon usa

inclusion criteria: 1. informed consent form signed. 2. patients with symptoms compatible with covid-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care. 3. positive polymerase chain reaction (pcr) or transcription-mediated amplification (tma) test or rapid antigen test for severe acute respiratory syndrome corona virus-2 (sars-cov-2) or diagnostic test available. 4. age ≥ 18 years 5. availability to meet the requirements of the protocol.

inclusion criteria: 1. informed consent form signed. 2. patients with symptoms compatible with covid-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care. 3. positive polymerase chain reaction (pcr) or transcription-mediated amplification (tma) test or rapid antigen test for severe acute respiratory syndrome corona virus-2 (sars-cov-2) or diagnostic test available. 4. age ≥ 18 years 5. availability to meet the requirements of the protocol.

Jan. 13, 2023, noon usa

inclusion criteria: informed consent form signed. patients with symptoms compatible with covid-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care. positive polymerase chain reaction (pcr) or transcription-mediated amplification (tma) test or rapid antigen test for severe acute respiratory syndrome corona virus-2 (sars-cov-2) or diagnostic test available. age ≥ 18 years availability to meet the requirements of the protocol.

inclusion criteria: informed consent form signed. patients with symptoms compatible with covid-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care. positive polymerase chain reaction (pcr) or transcription-mediated amplification (tma) test or rapid antigen test for severe acute respiratory syndrome corona virus-2 (sars-cov-2) or diagnostic test available. age ≥ 18 years availability to meet the requirements of the protocol.

Nov. 16, 2021, 6:30 p.m. usa

inclusion criteria: informed consent form signed. patients with symptoms compatible with covid-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care. positive polymerase chain reaction (pcr) or transcription-mediated amplification (tma) test or rapid antigen test for severe acute respiratory syndrome corona virus-2 (sars-cov-2) or diagnostic test available. age ≥ 65 years. age ≥ 45 years with 1 or more comorbidities (diabetes, hypertension, obesity, heart disease, respiratory disease). availability to meet the requirements of the protocol.

inclusion criteria: informed consent form signed. patients with symptoms compatible with covid-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care. positive polymerase chain reaction (pcr) or transcription-mediated amplification (tma) test or rapid antigen test for severe acute respiratory syndrome corona virus-2 (sars-cov-2) or diagnostic test available. age ≥ 65 years. age ≥ 45 years with 1 or more comorbidities (diabetes, hypertension, obesity, heart disease, respiratory disease). availability to meet the requirements of the protocol.

Feb. 16, 2021, 12:31 a.m. usa

inclusion criteria: 1. informed consent form signed. 2. patients with symptoms compatible with covid-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care. 3. positive polymerase chain reaction (pcr) or transcription-mediated amplification (tma) test or rapid antigen test for severe acute respiratory syndrome corona virus-2 (sars-cov-2) or diagnostic test available. 4. age ≥ 65 years. 5. age ≥ 45 years with 1 or more comorbidities (diabetes, hypertension, obesity, heart disease, respiratory disease). 6. availability to meet the requirements of the protocol.

inclusion criteria: 1. informed consent form signed. 2. patients with symptoms compatible with covid-19: cough and fever who not fulfil criteria of hospitalization and will be in outpatient care. 3. positive polymerase chain reaction (pcr) or transcription-mediated amplification (tma) test or rapid antigen test for severe acute respiratory syndrome corona virus-2 (sars-cov-2) or diagnostic test available. 4. age ≥ 65 years. 5. age ≥ 45 years with 1 or more comorbidities (diabetes, hypertension, obesity, heart disease, respiratory disease). 6. availability to meet the requirements of the protocol.